Phaseline

Companies › Emalex Biosciences

Emalex Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ecopipam
Dopamine D1 receptor antagonist
DRD1Phase 3Tourette SyndromeFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06021522EcopipamPhase 3Tourette SyndromePsychiatryFeb 2028

Targets

DRD1 (1)

Companies with the same targets

Serina Therapeutics

Companies built like this

Curemark Boston Medical Group Transcend Therapeutics Gedeon Richter Cybin IRL

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.